Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual Meeting

Share Name	Share Symbol	Market	Type
Transgene S.A. ADS (MM)	NASDAQ:TRGNY	NASDAQ	Ordinary Share

Share Name

Share Symbol

Market

Type

Transgene S.A. ADS (MM)

NASDAQ:TRGNY

NASDAQ

Ordinary Share

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.00

Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual Meeting

05/04/2005 6:01am

PR Newswire (US)

Transgene . (NASDAQ:TRGNY)
Historical Stock Chart

From Jun 2019 to Jun 2024

Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual Meeting STRASBOURG, France, April 5 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Eurolist Paris: FR0005175080) announced today that data from the MVA-MUC1-IL2 cancer vaccine Phase II trials in non-small cell lung and prostate cancers has been accepted for presentation at the 2005 Annual Meeting of ASCO (American Society of Clinical Oncology). The meeting will take place in Orlando, Florida, May 13-17, 2005. 1. Poster presentation: "A Phase II study evaluating the clinical efficacy of MVA-MUC1-IL2 (TG4010) in association with chemotherapy in patients with Non Small Cell Lung Cancer". Presented by Prof. Thierry Velu, Academic Erasme Hospital, Brussels, Belgium. 2. Oral presentation in the genito-urinary scientific program: "MVA-MUC1- IL2 vaccine immunotherapy (TG4010) in patients with prostate cancer with biochemical failure". Presented by Dr. Robert Dreicer, Cleveland Clinic Foundation, Cleveland, Ohio. "We are very pleased that two abstracts describing clinical results with our cancer vaccine MVA-MUC1-IL2 have been selected for presentation at this year's ASCO meeting," said Dr. Patrick Squiban, MD, VP, Medical and Regulatory Affairs of Transgene. "It will be an opportunity to communicate updated, additional data beyond the promising interim results that we have released up to now." About Transgene: Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicated to the discovery and development of therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. Transgene has a broad portfolio of products in clinical development. This press release contains a forward-looking statement regarding the potential efficacy of one of Transgene's cancer vaccine candidates. The results of clinical testing to date are preliminary and based upon a small number of patients. As is the case with all biopharmaceutical products under development, results from future studies with more data may show less favourable outcomes. DATASOURCE: Transgene CONTACT: Patrick Squiban, MD, VP, Medical and Regulartory Affairs, Transgene, +33-3-88-27-91-73; Michael Long, Cohn & Wolfe, +1-415-365-8523; Tiphaine Hecketsweiler of Image 7, +33-1-53-70-74-70, both for Transgene Web site: http://www.transgene.fr/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

TRGNY Transgene S.A. ADS (MM)